- Research article
- Open Access
The adjuvant G3 promotes a Th1 polarizing innate immune response in equine PBMC
© The Author(s) 2018
- Received: 17 April 2018
- Accepted: 1 October 2018
- Published: 22 October 2018
The immunomodulatory effect of a new particulate adjuvant, G3, alone or in combination with agonists to TLR2/1 or TLR5 was evaluated in cultures of equine PBMC. Exposure to the G3 adjuvant up-regulated genes encoding IFN-γ, IL-1β, IL-6, IL-8, IL-12p40 and IL-23p19 in the majority of the horses tested, indicating that the G3 adjuvant induced a pro-inflammatory and Th1 dominated profile. In accordance, genes encoding IL-13, IL-4, IL-10 and TGF-β remained unaffected and genes encoding IFN-α, IL-17A and TNF-α were only occasionally and weakly induced. The two TLR agonists Pam3CSK4 (TLR2/1) and FliC (TLR5) induced cytokine profiles characterized by a clear induction of IL-10 as well as up-regulation of the genes encoding IL-1β, IL-6 and IL-8. The presence of G3 modified this response, in particular by reducing the FliC and Pam3CSK4 induced production of IL-10. Furthermore, G3 acted in synergy with Pam3CSK4 in enhancing the production of IFN-γ whereas G3 combined with FliC increased the gene expression of IL-8. Thus, the G3 adjuvant seems to have the capacity to promote a Th1 polarizing innate immune response in eqPBMC, both by favouring IFN-γ production and by reducing production of IL-10 induced by co-delivered molecules. These features make G3 an interesting candidate to further evaluate for its potential as an adjuvant in equine vaccines.
A variety of adjuvants including aluminium salts, emulsions, carbomers and immune stimulatory complexes (ISCOMs) are today used in animal vaccines . Based on their physical form and mode of action, these adjuvants have been categorized as particulate formulations, immunomodulatory molecules or a combination thereof. Particulate formulations primarily enhance uptake by antigen presenting cells [2, 3] but may also modulate innate immune responses [4–6]. This effect can be further improved by inclusion of other immunomodulatory molecules in the vaccine formula. Accordingly, compounds such as Toll-like receptor (TLR) agonists, polyphosphazenes and cytokines are currently under investigation as additives in vaccines [1, 7, 8]. The best-known example of such an adjuvant complex is AS04 based on aluminium salts combined with the TLR4 agonist monophosphoryl lipid A . The strategy to combine adjuvant components in order to improve vaccine efficacy has also been examined for veterinary use, e.g. in vaccines for cattle, pigs and poultry .
In the present study, a novel adjuvant “G3” was evaluated in cultures of equine peripheral blood mononuclear cells (eqPBMC). The G3 adjuvant is a 20 nm particle formulated of cholesterol and QuilA components extracted from the tree Quillaja saponaria Molina that induce potent antibody and T cell responses to H1N1 influenza virus (Patent no. WO 2013/05/1994). Subsequent evaluations  demonstrate that G3 with an incorporated diterpene enhances immune protection to H1N1 influenza virus in mice challenged with a strain antigenically distinct from that used for immunisation. This protection was based on cytotoxic T lymphocytes targeting the nucleoprotein and polymerase A. A similar Th1 polarization was indicated by induction of IFN-γ/IL-2 double producing cells as determined by FluoroSpot and production of IgG2a in mice immunized with G3 adjuvanted influenza antigens . In vitro, G3 alone induced IFN-γ production as well as increased the expression of maturation markers in cultures of human monocyte-derived dendritic cells .
The present study evaluated effects by G3 on eqPBMC stand alone or in combination with the TLR2/1 agonist Pam3CSK4 or the TLR5 agonist FliC. Both the recombinant flagellin protein FliC and the synthetic triacylated lipoprotein Pam3CSK4 have been extensively studied in several species and successfully included in several vaccine constructs [reviewed in 12, 13], but only limited data are available on their effects in the horse [14–17]. We were therefore motivated to study cytokine profiles of eqPBMC cultured in the presence of these two compounds stand alone or in combination with G3. As read out, transcription of cytokine genes was measured by qPCR and the production of IFN-γ and IL-10 was verified by ELISA.
Isolation of eqPBMC
Healthy horses housed at the Department of Clinical Sciences, SLU, Uppsala, Sweden were used in the study. These horses (Swedish Warmblood, geldings and mares, age 9–14 years) are clinically examined including complete blood counts, and vaccinated for tetanus and influenza on a regular basis. The sampling was approved by the Ethical Committee for Animal Experiments in Uppsala. Blood was collected in heparinized tubes from the jugular vein. After 15–20 min sedimentation, blood plasma was collected and eqPBMC were isolated by centrifugation on Ficoll Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). Cells were washed three times in PBS and suspended in growth medium, i.e. RPMI 1640 medium (BioWhittaker, Cambrex Bioscience, Verviers, Belgium) supplemented with HEPES (20 mM), l-glutamine (2 mM), penicillin (200 IU/mL), streptomycin (100 µg/mL), 2-mercaptoethanol (50 µM), and 5% fetal calf serum (Invitrogen, Life Technologies, Carlsbad, CA, USA).
Culture conditions for gene expression analysis
Between 5 and 10 × 106 eqPBMC in one mL medium were seeded in 6-well plates (Nunclon; Nunc, Roskilde, Denmark), incubated for 30 min at 37 °C in 7% CO2, whereafter one mL of the adjuvant “G3” (MoreinX AB, Uppsala, Sweden) at final concentrations 1, 3 or 5 µg/mL was added to the cultures. PBMCs were also cultured in the presence of either FliC (0.1 µg/mL; VacciGrade™, InvivoGen, San Diego, CA, USA), Pam3CSK4 (0.5 µg/mL; InvivoGen) or G3 (3 µg/mL), or in combinations thereof. The combinations of G3 with FliC or Pam3CSK4 were pre-incubated for 15 min in growth medium before being added to the cultures. After 18 h, cells were harvested for gene transcription analysis. As controls, freshly isolated eqPBMC or eqPBMC cultured in plain growth medium for 18 h were used.
RNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis were performed as previously described . In brief, RNA was extracted by combining Trizol (Invitrogen, Carlsbad, CA, USA) with the column-based E.Z.N.A. total RNA kit (Omega Biotek, Norcross, GA, USA). RNA quantity and purity was estimated by spectrophotometry (NanoDrop ND-1000, NanoDrop Technologies, Montchanin, DE, USA) and RNA quality index (RQI) was estimated to ≥ 9.8 using capillary gel electrophoresis (Experion RNA StdSense Analysis Kit, Bio-Rad Laboratories, Solna, Sweden). After treating 0.4–1 μg of RNA with RQ1 RNAse-free DNAse (Promega, Madison, WI, USA) cDNA was synthesized (GoScript Reverse transcription system; Promega) and diluted 5 × before storage at −20 °C.
Published primer pairs for genes encoding equine IFN-α, IFN-γ, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-13, IL-17A, IL-23p19, TGF-β, and TNF-α were used under conditions optimised in house (Additional file 1). Duplicate reactions of 2 µL cDNA in 23 µL Quantitect SYBR Green PCR mix (Qiagen) were run in an IQ5 or a CFX96 Touch PCR machine (Bio-Rad) with an initial cycle of 95 °C for 15 min followed by 40 cycles of 95 °C for 15 s, the assay specific annealing temperature for 30 s and 72 °C for 30 s. Five reference genes; β2M, HPRT, RPL32, SDHA and TFRC , were evaluated for their expression stability in eqPBMC stimulated or not with G3 using the geNorm software (qBasePLUS, Biogazelle). The genes were scored based on a gene stability parameter (M) and a coefficient of variation (CV), where M values < 0.5 and CV values < 0.2 indicate high expression stability. The genes RPL32 (M = 0.339; CV = 0.128) and SDHA (M = 0.329; CV = 0.117) were accordingly selected for normalization prior to calibration of stimulated samples to their medium controls . Genes reaching fold change (FC) values < 0.5 or > 2 were considered as differentially expressed.
Culture conditions for analysis of IFN-γ and IL-10 production
EqPBMC (4 × 105 in 100 µL medium) were incubated for 30 min in 96-well round bottom plates (Nunc) before addition of 100 µL growth medium containing G3 (final concentration: 3 or 5 µg/mL), FliC (0.1 µg/mL), Pam3CSK4 (0.5 µg/mL) or G3 mixed with FliC or Pam3CSK4. As controls, eqPBMC were cultured in plain growth medium or in the presence of phorbol 12-myristate 13-acetate (PMA; 0.05 µg/mL; Sigma-Aldrich®) and Ionomycin (1 µg/mL; Sigma-Aldrich®). Cell supernatants were collected after 48 h and stored at −20 °C until analysed for the presence of IFN-γ or IL-10 using commercial ELISA kits (Equine IFN-γ development kit, Mabtech, Nacka strand, Sweden; Equine IL-10 ELISA Kit, Thermo Scientific, Frederick, MD, USA) according to the manufacturer’s instructions.
EqPBMC (2.5–5 × 106 cells/mL) were seeded in 6-well plates and stimulated with G3 (5 µg/mL) and Pam3CSK4 (0.5 µg/mL) added simultaneously or sequentially (6 or 12 h apart). Cells were harvested 18 h after the first stimuli and analysed for IFN-γ mRNA expression. In addition, eqPBMC (4 × 106 cells/mL) were seeded in 96-well round bottom plates and stimulated with G3 and Pam3CSK4 added simultaneously or sequentially after 2, 4, 6 or 8 h. In parallel, G3 or Pam3CSK4 were added alone after 0, 2, 4, 6 and 8 h of culture. All supernatants were collected after a total culture time of 48 h and stored at −20 °C until analysed for the presence of IFN-γ.
Statistical analysis was performed using the software Prism 5.0 (Graphpad Software, Inc., CA, USA). Normal distribution of data was confirmed using the Kolmogorov–Smirnov test. Differences between treatments were determined using the repeated measures ANOVA followed by Tukey’s multiple comparison test where P-values < 0.05 were regarded as significant. When indicated, variability of gene expression data is reported as mean ± SD.
Transcriptional response to G3
Transcriptional response to G3 and TLR agonists
G3 inhibits IL-10 production
The inhibition of IL-10 gene transcription was also reflected at the protein level in eqPBMC after incubation for 48 h in the presence of G3 and Pam3CSK4 (Figure 4B) or FliC (Figure 4D). After subtraction of the spontaneous production of IL-10 recorded in control cultures (range 0.7–1.2 ng IL-10/mL medium), the levels of IL-10 in supernatants from eqPBMC exposed to PMA/ionomycin ranged from 8.6 to 12.2 ng/mL. FliC and Pam3CSK4 alone induced concentrations between 0.6 and 1.3 and 1.0–1.8 ng IL-10/mL, respectively, which were significantly reduced (P < 0.001) by the presence of G3.
G3 combined with Pam3CSK4 enhance production of IFN-γ
Effects of order and time elapse between addition of G3 and Pam3CSK4 on IFN-γ production
To study this effect in further detail at the protein level, IFN-γ induced by G3 and Pam3CSK4 added within closer intervals were at each occasion (2, 4, 6 and 8 h) compared to that in parallel cultures stimulated by G3 or Pam3CSK4 alone (Figure 6B). In line with the transcript analysis, the order of addition was not pivotal for the IFN-γ increase and simultaneous addition of G3 and Pam3CSK4 generated significantly higher (P < 0.001) concentrations of IFN-γ compared to that induced by G3 or Pam3CSK4 alone. The enhancing effect remained when G3 and Pam3CSK4 were added up to 6 h apart (P < 0.05).
The present study was conducted to explore the possibility to modulate immune reactions using the G3 adjuvant stand alone or in combination with Pam3CSK4 or FliC. The magnitude of the responses to G3, FliC or Pam3CSK4 varied between PBMC collected from different horses. Therefore, the responses to the various cytokine inducers, or combinations of those, were compared within each individual. Inter-individual variations in cytokine responses are found in most mammalian species, including the horse [20–23], which can be explained by genetic as well as environmental factors. Despite these variations, distinct patterns of gene regulation was revealed at stimulation with G3 or any of the two TLR agonists. Thus, it can be assumed that the large variation recorded for the IFN-γ and IL-8 responses in the present study, reflects that of an out-bred population of vaccine recipients.
Both Pam3CSK4 and FliC tended to up-regulate the genes encoding IL-1β, IL-6, IL-8 and IL-10. Previous studies conducted in the horse using flagellin reveal an increased expression of the genes for IL-6 and IL-8 in primary cultures of equine keratinocytes  as well as for TNF-α and IL-10 in equine neutrophils . Thus, flagellin/FliC seems to induce similar cytokine responses in equine cells as in other species . Likewise, Pam3CSK4 induces equine monocytes to produce IL-1β, IL-6, IL-10 and TNF-α  as it does in human and murine cells [25, 26]. In the present study, Pam3CSK4 did not induce gene expression of TNF-α, possibly explained by a spontaneous increase in gene expression of TNF-α seen after 18 h of incubation (data not shown) being congruent with a high spontaneous release of TNF-α found in supernatants of unstimulated eqPBMC . Also, a spontaneous induction of IL-1β was recorded in the control cultures. However, the gene expression of IL-1β increased further by the presence of Pam3CSK4, in agreement with previous observations where stimulation with Pam3CSK4 induced higher levels of IL-1β compared to TNF-α in cultures of equine monocytes . Furthermore, the expression of TNF-α is almost instant and was not detectable after 2 h culture of equine whole blood exposed to LPS . Thus, it cannot be excluded that G3 induced a rapid transient production of TNF-α which was not detected in the present experimental set-up. Regardless, FliC and Pam3CSK4 are useful tools to delineate cytokine responses in cultures of eqPBMC.
The increase of IL-8 and IFN-γ in response to G3 combined with FliC or Pam3CSK4 was more than additive, indicating synergy. Stimulation of multiple pattern recognition receptors (PRRs) are considered important for tailoring the innate cytokine production . Indeed, several studies report synergistic activation of innate and adaptive immune responses by combining multiple TLR agonists in a vaccine [7, 29–32]. Considering that most pathogens contain multiple PAMPs, activation of more than one receptor is probably important for the host to mount effective immune responses to infections. These results are in line with earlier studies  showing that G3 alone induced CD8+ T cells as well as antibodies specific for influenza virus antigens in mice, but protection against challenge with a heterologous influenza virus strain was only achieved when G3 was formulated with an additional immunostimulant, i.e., a steviol glycoside .
Several studies report preserved synergy effects by sequential stimulation of PRRs [34–36]. Therefore, the kinetics behind the synergy effects seen on IFN-γ production was studied by adding G3 and Pam3CSK4 to eqPBMC in different order and at different time points. Enhanced production of IFN-γ was retained when G3 and Pam3CSK4 were added within a 2–6 h time window, indicating that the synergy on IFN-γ production was due to an indirect rather than a direct interaction between G3 and Pam3CSK4. The synergy effect was also independent of the order of addition, suggesting that both inducers may have “priming” capacities . The enhancement of IFN-γ production can possibly explain why the presence of G3 reduced the production of IL-10 induced by both TLR agonists. However, the modes of action behind synergistic and negative cross-talks between PRRs are largely unclear and is probably affected by a range of factors .
The immunomodulatory component of G3 is the saponin Quil A, here formulated into nanoparticles with cholesterol. A proposed mechanisms involved in the adjuvant activity of Quil A was recently reviewed , suggesting that T cells could be directly activated by saponin aldehyde side chains interacting with amino acid residues present in the TCRs. Another possible interaction is through sugar moieties binding to lectin receptors on immune cells [40, 41]. Thus, it is likely that G3 physically interacts with cellular receptors and starts a signalling cascade that can be further modified by inclusion of other immunomodulatory compounds. Taken together, the adjuvant G3 seems to polarize the immune response by inducing a cytokine profile dominated by pro-inflammatory and Th1-associated cytokines. This profiling is highly desired for vaccines against pathogens where immune protection largely depends on cell-mediated immunity. Therefore, these results make it interesting to further evaluate the potential of G3 as an adjuvant in equine vaccines.
BM developed the G3 adjuvant (Patent No. WO 2013/05/1994 April 2013). Other authors declares no competing interests.
SH planned the study together with BH and CF, performed the laboratory experiments and analysed the data. BH has made contributions to sample preparation, qPCR design and participated in analysing data. CF contributed to evaluate results and work on manuscript. BM advised on adjuvant experiment set-up. All authors read and approved the final manuscript.
We gratefully acknowledge Mari Wallbring and Carola Jansson for helping to collect blood samples. Many thanks to Prof. Marianne Jensen Waern and Assoc. Prof. Eva Tydén for valuable advices and constructive criticism on the manuscript.
Ethics approval and consent to participate
The blood sampling made in the current study was approved by the Ethical Committee for Animal Experiments in Uppsala.
This work was funded by the Swedish-Norwegian Foundation for Equine Research (H-16-47-193) and the Royal Swedish Academy of Agriculture and Forestry (GFS2015-0140).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Burakova Y, Madera R, McVey S, Schlup JR, Shi J (2017) Adjuvants for animal vaccines. Viral Immunol 31:11–22View ArticleGoogle Scholar
- Cox JC, Coulter AR (1997) Adjuvants—a classification and review of their modes of action. Vaccine 15:248–256View ArticleGoogle Scholar
- Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597–1608View ArticleGoogle Scholar
- Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E (2012) MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 188:3088–3098View ArticleGoogle Scholar
- Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouhabi A, Harvengt P, Carlsen H, Kjelland A, Chomez P, Garçon N, Van Mechelen M (2011) Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461–2473View ArticleGoogle Scholar
- Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180:5402–5412View ArticleGoogle Scholar
- Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196View ArticleGoogle Scholar
- Vasou A, Sultanoglu N, Goodbourn S, Randall RE, Kostrikis LG (2017) Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses 9:E186View ArticleGoogle Scholar
- Garçon N, Van Mechelen M (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10:471–486View ArticleGoogle Scholar
- van de Sandt CE, Kreijtz JHCM, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, Osterhaus AD, Morein B, Rimmelzwaan GF (2014) Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine 32:5614–5623View ArticleGoogle Scholar
- Hjertner B, Bengtsson T, Morein B, Paulie S, Fossum C (2018) A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine. Vaccine 36:3340–3344View ArticleGoogle Scholar
- Basto AP, Leitão A (2014) Targeting TLR2 for vaccine development. J Immunol Res 2014:619410View ArticleGoogle Scholar
- Hajam IA, Dar PA, Shahnawaz I, Jaume JC, Lee JH (2017) Bacterial flagellin—a potent immunomodulatory agent. Exp Mol Med 49:e373View ArticleGoogle Scholar
- Figueiredo MD, Vandenplas ML, Hurley DJ, Moore JN (2009) Differential induction of MyD88- and TRIF-dependent pathways in equine monocytes by Toll-like receptor agonists. Vet Immunol Immunopathol 127:125–134View ArticleGoogle Scholar
- Irvine KL, Hopkins LJ, Gangloff M, Bryant CE (2013) The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet Res 44:50View ArticleGoogle Scholar
- Kwon S, Gewirtz AT, Hurley DJ, Robertson TP, Moore JN, Vandenplas ML (2011) Disparities in TLR5 expression and responsiveness to flagellin in equine neutrophils and mononuclear phagocytes. J Immunol 186:6263–6270View ArticleGoogle Scholar
- Leise BS, Yin C, Pettigrew A, Belknap JK (2010) Proinflammatory cytokine responses of cultured equine keratinocytes to bacterial pathogen-associated molecular pattern motifs. Equine Vet J 42:294–303View ArticleGoogle Scholar
- Hjertner B, Olofsson KM, Lindberg R, Fuxler L, Fossum C (2013) Expression of reference genes and T helper 17 associated cytokine genes in the equine intestinal tract. Vet J 197:817–823View ArticleGoogle Scholar
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034View ArticleGoogle Scholar
- Horín P, Smola J, Matiasovic J, Vyskocil M, Lukeszová L, Tomanová K, Králík P, Glasnák V, Schröffelová D, Knoll A, Sedlinská M, Krenková L, Jahn P (2004) Polymorphisms in equine immune response genes and their associations with infections. Mamm Genome 15:843–850View ArticleGoogle Scholar
- Liston A, Carr EJ, Linterman MA (2016) Shaping variation in the human immune system. Trends Immunol 37:637–646View ArticleGoogle Scholar
- Schnabel CL, Steinig P, Schuberth H-J, Koy M, Wagner B, Wittig B, Juhls C, Willenbrock S, Murua Escobar E, Jaehnig P, Feige K, Cavalleri JM (2015) Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release. Vet Immunol Immunopathol 165:64–74View ArticleGoogle Scholar
- Werners AH, Bull S, Vendrig JC, Smyth T, Bosch RR, Fink-Gremmels J, Bryant CE (2006) Genotyping of Toll-like receptor 4, myeloid differentiation factor 2 and CD-14 in the horse: an investigation into the influence of genetic polymorphisms on the LPS induced TNF-alpha response in equine whole blood. Vet Immunol Immunopathol 111:165–173View ArticleGoogle Scholar
- Mizel SB, Bates JT (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677–5682View ArticleGoogle Scholar
- Funderburg NT, Jadlowsky JK, Lederman MM, Feng Z, Weinberg A, Sieg SF (2011) The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytes. Immunology 134:151–160View ArticleGoogle Scholar
- Motoi Y, Shibata T, Takahashi K, Kanno A, Murakami Y, Li X, Kasahara T, Miyake K (2014) Lipopeptides are signaled by Toll-like receptor 1, 2 and 6 in endolysosomes. Int Immunol 26:563–573View ArticleGoogle Scholar
- Vinther AML, Skovgaard K, Heegaard PMH, Andersen PH (2015) Dynamic expression of leukocyte innate immune genes in whole blood from horses with lipopolysaccharide-induced acute systemic inflammation. Vet Res 11:134Google Scholar
- Tan RST, Ho B, Leung BP, Ding JL (2014) TLR cross-talk confers specificity to innate immunity. Int Rev Immunol 33:443–453View ArticleGoogle Scholar
- Abhyankar MM, Noor Z, Tomai MA, Elvecrog J, Fox CB, Petri WA (2016) Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine 35:916–922View ArticleGoogle Scholar
- Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, Coblentz D, Reed SG, Carter D (2014) A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7. J Nanobiotechnology 12:17View ArticleGoogle Scholar
- Kreutz M, Bakdash G, Dolen Y, Sköld AE, van Hout-Kuijer MA, de Vries IJM, Figdor CG (2015) Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists. Eur J Immunol 45:2798–2809View ArticleGoogle Scholar
- Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN (2014) A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 2014:e83884View ArticleGoogle Scholar
- Sehar I, Kaul A, Bani S, Pal HC, Saxena AK (2008) Immune up regulatory response of a non-caloric natural sweetener, stevioside. Chem Biol Interact 173:115–121View ArticleGoogle Scholar
- Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776View ArticleGoogle Scholar
- Speth MT, Repnik U, Müller E, Spanier J, Kalinke U, Corthay A, Griffiths G (2017) Poly(I:C)-encapsulating nanoparticles enhance innate immune responses to the tuberculosis vaccine bacille Calmette-Guérin (BCG) via synergistic activation of innate immune receptors. Mol Pharm 14:4098–4112View ArticleGoogle Scholar
- Tremblay MM, Bilal MY, Houtman JCD (2013) Prior TLR5 induction in human T cells results in a transient potentiation of subsequent TCR-induced cytokine production. Mol Immunol 57:161–170View ArticleGoogle Scholar
- Borges da Silva H, Fonseca R, Alvarez JM, D’Império Lima MR (2015) IFN-γ priming effects on the maintenance of effector memory CD4(+) T cells and on phagocyte function: evidences from infectious diseases. J Immunol Res 2015:202816View ArticleGoogle Scholar
- Jain A, Pasare C (2017) Innate control of adaptive immunity: beyond the three-signal paradigm. J Immunol 198:3791–3800View ArticleGoogle Scholar
- Bonam SR, Partidos CD, Halmuthur SKM, Muller S (2017) An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci 38:771–793View ArticleGoogle Scholar
- Sun H-X, Xie Y, Ye Y-P (2009) Advances in saponin-based adjuvants. Vaccine 27:1787–1796View ArticleGoogle Scholar
- Marciani DJ (2015) Is fucose the answer to the immunomodulatory paradox of Quillaja saponins? Int Immunopharmacol 29:908–913View ArticleGoogle Scholar